IN VITRO AND IN SILICO EVALUATION OF THYMOQUINONE AS POTENTIAL ANTICANCER AGENT IN HUMAN ACUTE MYELOID LEUKEMIA HL-60 CELLS

This study aims to explore the cytotoxic, apoptotic and autophagic effects of thymoquinone on human acute myeloid leukemia. The cytotoxic were determined with 3-(4, 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide (MTT) tests. B-cell lymphoma 2 associated X protein (Bax), (Bcl-2), caspase 3, mammalian target rapamycin (mTOR), phosphatidylinositol-3-kinase (PI3K), kinase B (AKT) gene expression analyzes studied quantitative real-time polymerase chain reaction (qRT-PCR). AutoDock Tools 4.2 software was applied research potential binding in active sites Bax, Bcl-2, mTOR, PI3K, AKT proteins. Thymoquinone caused a effect HL-60 cells (Human leukemia cell line) value 16.35 µM. Bcl-2 decreased all concentrations compared control. A decrease 3 level detected treated 10 µM, 15 25 µM induced an important mTOR PI3K expressions control at doses, while dose docking outcomes showed that interacts site amino acids proteins via hydrophobic interactions hydrogen bonding. present findings suggest can stimulate autophagy by prevention PI3K/AKT/mTOR pathway may become new for therapy